|Bid||73.22 x 1800|
|Ask||73.34 x 1200|
|Day's Range||72.66 - 74.25|
|52 Week Range||68.44 - 91.40|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||25.88|
|Forward Dividend & Yield||2.76 (3.74%)|
|Ex-Dividend Date||Dec. 14, 2021|
|1y Target Est||N/A|
Shares of pharma giant Merck (NYSE: MRK) fell by 14.9% during the month of November, according to data from S&P Global Market Intelligence. Although the drugmaker did take a hit from a clinical setback for its once-weekly oral treatment, MK-8507, for HIV-1 infection last month, the main reason Merck's stock slumped in November is the evolving situation surrounding its oral coronavirus pill molnupiravir. In brief, this COVID-19 pill, which is being jointly developed with privately held Ridgeback Biotherapeutics, exhibited a significant drop in efficacy following the final analysis of the full data set, compared to a prior interim data readout.
Merck & Co., Inc. ( NYSE:MRK ) has announced that it will be increasing its dividend on the 7th of January to US$0.69...
Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?